Human immunodeficiency virus type 1 latency model for high-throughput screening.
Human immunodeficiency virus type 1 (HIV-1) is not eliminated from patients even after years of antiretroviral therapy, apparently due to the presence of latently infected cells. Here we describe the development of a cell-based system of latency that can be used for high-throughput screening aimed at novel drug discovery to eradicate HIV-1 infection.
Micheva-Viteva
Sofiya
S
Department of Molecular Genetics, Microbiology and Immunology, UMDNJ-Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, New Jersey 08854, USA.
Pacchia
Annmarie L
AL
Ron
Yacov
Y
Peltz
Stuart W
SW
Dougherty
Joseph P
JP
D019380:Anti-HIV Agents / Q000494:pharmacology*; D023241:Antiretroviral Therapy, Highly Active; D015658:HIV Infections / Q000503:physiopathology*; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008954:Models, Biological; D017735:Virus Latency / Q000502:physiology*; D014779:Virus Replication / Q000187:drug effects
D019380:Anti-HIV Agents